| Autor: |
Thomas M. Berghaus, Stefanie Bader, Christian Faul, Sabine Haberl, Florian Schwarz, Alessandro Liebich, Alexander Dierks, Malte Kircher, Constantin Lapa, Christian H. Pfob |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Respiratory Research. 23 |
| ISSN: |
1465-993X |
| DOI: |
10.1186/s12931-022-02188-2 |
| Popis: |
Background Anticoagulant treatment is recommended for at least three months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related acute pulmonary embolism (PE), but the persistent pulmonary clot burden after that time is unknown. Methods Lung perfusion was assessed by ventilation-perfusion (V/Q) SPECT/CT in 20 consecutive patients with SARS-CoV-2-associated acute PE after a minimum of three months anticoagulation therapy in a retrospective observational study. Results Remaining perfusion defects after a median treatment period of six months were observed in only two patients. All patients (13 men, seven women, mean age 55.6 ± 14.5 years) were on non-vitamin K direct oral anticoagulants (DOACs). No recurrent venous thromboembolism or anticoagulant-related bleeding complications were observed. Among patients with partial clinical recovery, high-risk PE and persistent pulmonary infiltrates were significantly more frequent (p Interpretation Temporary DOAC treatment seems to be safe and efficacious for resolving pulmonary clot burden in SARS-CoV-2-associated acute PE. Partial clinical recovery is more likely caused by prolonged SARS-CoV-2-related parenchymal lung damage rather than by persistent pulmonary perfusion defects. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink